Gocovri Generic: When Will Generic Amantadine Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Gocovri Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? March 2030 About 3.5 years away Why then?
- Has the FDA approved a generic? August 1986 17 companies approved
- When does the brand’s protection end? August 2038 The last of 13 listed patents Why sooner?
- Can you buy a generic today? Yes 46 companies list one
Dr. Brian Staiger Explains
PharmD, BCPS · Clinical pharmacistIt already is. A generic amantadine hydrochloride is listed for sale by 46 companies, so ask your pharmacy whether it can fill your prescription with one.
Why March 2030?
The brand company and a generic maker settled their patent fight and agreed on when a generic can launch. We rate it very likely: few things could still move it, but a court ruling or a new deal can.
If Gocovri’s protection runs to August 2038, how can a generic come sooner?
The 12 patents that run past the expected month, to August 2038 (8,741,343, 9,867,791, 9,867,792, 9,867,793 and 8 more), cover a way of using it and the product’s formulation. A patent like that protects one way of making or using the medicine, not the medicine itself. A generic company can often make its version a different way or leave that use off its label, or a court can rule the patent invalid or not infringed. Here, a settlement between the companies sets the date. Generic companies have been challenging Gocovri’s patents with the FDA since January 2018. That is why the expected month comes before the last protection ends. See the road to a generic
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Gocovri, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Gocovri by the Numbers
- Reason
- Settlement between companiesThe brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
- How sure
- Very likely Few things could still move it, but a court ruling or a new deal can.
- Price competition
- Moderate 2 companies have filed, 2 first in line
- Brand sales
- $265M a yearBig seller
- FDA approved 2017 August 2017 FDA Orange Book
- Patents listed 13 last runs to August 2038 FDA Orange Book
- Generics FDA-approved 17 companies, the first approved August 1986 FDA Orange Book
- Medicare Part D spent $123.9M in 2025, for 5,677 people CMS Part D Spending by Drug
- Medicaid prescriptions 972 in the last four reported quarters, $3.5M CMS Medicaid drug utilization, to Q1 2026
Gocovri’s Road to a Generic
Gocovri has had the market to itself since the FDA approved it in August 2017 (Supernus Pharmaceuticals Inc). Its 13 listed patents run to August 2038. Generic companies have challenged its patents with the FDA since January 2018.
The first generic of Gocovri is expected in March 2030.
Why that month: the brand company and a generic maker settled their patent fight and agreed on when a generic can launch. That is about 8.5 years before the last listed patent runs out, in August 2038.
Why a Generic Can Come Before August 2038
The last listed patent runs to August 2038, but it covers a way of using it and the product’s formulation, not the medicine itself, which a generic can often work around or challenge. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Gocovri Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Gocovri’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 8,389,578 | A way of using it (U-2105) | January 2028 | Active |
| 8,741,343 | A way of using it (U-2106) | December 2030 | Active |
| 9,867,791 | A way of using it (U-2106) | December 2030 | Active |
| 9,867,792 | A way of using it (U-2106) | December 2030 | Active |
| 9,867,793 | A way of using it (U-2106) | December 2030 | Active |
| 9,877,933 | A way of using it (U-2224) | December 2030 | Active |
| 11,197,835 | A way of using it (U-2106) | December 2030 | Active |
| 10,646,456 | A way of using it (U-2808) | June 2034 | Active |
| 11,903,908 | A way of using it (U-3822) | June 2034 | Active |
| 10,154,971 | A way of using it (U-2459) | December 2034 | Active |
| 11,065,213 | The product’s formulation | August 2038 | Active |
| 11,077,073 | A way of using it (U-2106, U-2224, U-3180) | August 2038 | Active |
| 12,233,033 | A way of using it (U-2106, U-3180, U-2224) | August 2038 | Active |
Source: FDA Orange Book, application 208944. Patent numbers open the patent on Google Patents.
Patent Challenges to Gocovri
The first patent challenge to Gocovri reached the FDA in January 2018, from one company on that first day. The FDA’s list has 2 entries for Gocovri, by form and strength. The FDA approved a first challenger’s generic in August 2024, and the list records no sale by a first challenger yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Gocovri’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Extended-release capsules, 137 mg | January 2018 | 1 company | Not posted | Not posted | Not posted | December 2030 |
| Extended-release capsules, 68.5 mg | April 2020 | 1 company | First challenger eligible decided September 2024 | August 2024 | Not yet | December 2034 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Amantadine Hydrochloride
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
At least 17 companies have applied to the FDA to make generic amantadine hydrochloride.
First in line. 2 of them were first in line, both filing on the first day any company did: they can share 180 days on the market before the other generics, which is why being first matters.
Generic companies have challenged Gocovri’s patents with the FDA since January 2018: see the patent challenges.
Approved by the FDA
The FDA has approved generic versions from 17 companies, the first in August 1986. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
For Sale in Pharmacies
Yes. A generic amantadine hydrochloride is listed for sale by 46 companies. Ask your pharmacy whether it can fill your prescription with it.
A-S Medication Solutions, Actavis Pharma, Inc., Advagen Pharma Limited, Akorn, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited and 34 more
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Upsher Smith Laboratories LLC | August 1986 | 100MG | AB |
| Sandoz Inc | February 1987 | 100MG | AB |
| Chartwell Rx Sciences LLC | June 1993 | 50MG/5ML | AA |
| Aurobindo Pharma USA Inc | October 1994 | 50MG/5ML | AA |
| Pharmaceutical Associates Inc | July 1995 | 50MG/5ML | AA |
| Pharmobedient Consulting LLC | December 1998 | 50MG/5ML | AA |
| Bionpharma Inc | May 2008 | 100MG | AB |
| Zydus Pharmaceuticals USA Inc | May 2016 | 100MG | AB |
| Strides Pharma Global Pte Ltd | June 2017 | 100MG | AB |
| Heritage Pharma Labs Inc | June 2017 | 100MG | AB |
| Alembic Pharmaceuticals Ltd | June 2017 | 100MG | AB |
| Rising Pharma Holdings Inc | March 2020 | 100MG | AB |
| Pom Pharma Ltd | March 2020 | 50MG/5ML, 100MG | AA, AB |
| Rubicon Research Ltd | May 2020 | 100MG | AB |
| Onesource Softgels Pte Ltd | February 2022 | 100MG | AB |
| Humanwell Puracap Pharmaceutical Wuhan Co Ltd | December 2022 | 100MG | AB |
| Zhejiang Jutai Pharmaceutical Co Ltd | September 2024 | 100MG | AB |
| Solvay Pharmaceuticals discontinued | September 1986 | 100MG | – |
| Watson Laboratories Inc discontinued | January 1987 | 100MG | – |
| G And W Laboratories Inc discontinued | October 1990 | 50MG/5ML | – |
| Teva Pharmaceuticals USA discontinued | August 1991 | 50MG/5ML | – |
| Adaptis Pharma Private Ltd discontinued | September 2002 | 50MG/5ML, 100MG | – |
| Actavis Elizabeth LLC discontinued | February 2006 | 100MG | – |
| Ph Health Ltd discontinued | December 2006 | 50MG/5ML | – |
| Invagen Pharmaceuticals Inc discontinued | September 2016 | 100MG | – |
| Chartwell Molecular Holdings LLC discontinued | June 2017 | 100MG | – |
| Jubilant Generics Ltd discontinued | February 2018 | 100MG | – |
| Zydus Worldwide Dmcc discontinued | August 2024 | EQ 68.5MG BASE | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Gocovri Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Gocovri, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Gocovri
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Gocovri, before manufacturer rebates.
- $29.5M
- January to March 2026, the latest CMS has posted
For 4,248 people, about $3,079 per prescription fill - $123.9M
- 2025, the whole year
For 5,677 people, about $3,115 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $29,492,078 | 4,248 | $3,078.51 |
| 2025 | $123,894,097 | 5,677 | $3,114.72 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Gocovri only, so no generic is counted in it. What CMS says it is used for: This medication is used to treat Parkinson's disease. It is also used to treat certain movement disorders caused by some drugs (extrapyramidal reactions).
Medicaid Prescriptions by Quarter
972 prescriptions in the four quarters to Q1 2026, $3.5M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 200 | $732,503 |
| Q4 2025 | 255 | $940,732 |
| Q3 2025 | 274 | $968,211 |
| Q2 2025 | 243 | $852,269 |
| Q1 2025 | 250 | $831,342 |
Source: CMS Medicaid State Drug Utilization Data, over Gocovri’s own package codes.
Gocovri Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 137MG BASE | Capsule, extended release | Oral | August 2017 | Prescription reference product |
| EQ 68.5MG BASE | Capsule, extended release | Oral | August 2017 | Prescription reference product |
Source: FDA Orange Book, Supernus Pharmaceuticals Inc. Listed for sale today by Adamas Pharma, LLC, Supernus Pharmaceuticals and Supernus Pharmaceuticals, Inc. (FDA NDC Directory).
Gocovri NDC Codes and Packages
Each Gocovri package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 17772-0170-21 | AMANTADINE 137 mg/1 capsule, coated pellets | bottle of 21 capsules | Supernus Pharmaceuticals, Inc. |
| 17772-0170-60 | AMANTADINE 137 mg/1 capsule, coated pellets | bottle of 60 capsules | Supernus Pharmaceuticals, Inc. |
| 70482-0170-21 | AMANTADINE 137 mg/1 capsule, coated pellets | bottle of 21 capsules | Adamas Pharma, LLC |
| 70482-0170-21 | AMANTADINE 137 mg/1 capsule, coated pellets | bottle of 21 capsules | Adamas Pharma, LLC |
| 70482-0170-60 | AMANTADINE 137 mg/1 capsule, coated pellets | bottle of 60 capsules | Adamas Pharma, LLC |
| 70482-0170-60 | AMANTADINE 137 mg/1 capsule, coated pellets | bottle of 60 capsules | Adamas Pharma, LLC |
| 70482-0170-61 | AMANTADINE 137 mg/1 capsule, coated pellets | bottle of 60 capsules | Adamas Pharma, LLC |
| 70482-0170-61 | AMANTADINE 137 mg/1 capsule, coated pellets | bottle of 60 capsules | Adamas Pharma, LLC |
Show the other 8 Gocovri packages
| NDC | Product | Package | Company |
|---|---|---|---|
| 17772-0085-21 | AMANTADINE 68.5 mg/1 capsule, coated pellets | bottle of 21 capsules | Supernus Pharmaceuticals, Inc. |
| 17772-0085-60 | AMANTADINE 68.5 mg/1 capsule, coated pellets | bottle of 60 capsules | Supernus Pharmaceuticals, Inc. |
| 70482-0085-21 | AMANTADINE 68.5 mg/1 capsule, coated pellets | bottle of 21 capsules | Adamas Pharma, LLC |
| 70482-0085-21 | AMANTADINE 68.5 mg/1 capsule, coated pellets | bottle of 21 capsules | Adamas Pharma, LLC |
| 70482-0085-60 | AMANTADINE 68.5 mg/1 capsule, coated pellets | bottle of 60 capsules | Adamas Pharma, LLC |
| 70482-0085-60 | AMANTADINE 68.5 mg/1 capsule, coated pellets | bottle of 60 capsules | Adamas Pharma, LLC |
| 70482-0085-61 | AMANTADINE 68.5 mg/1 capsule, coated pellets | bottle of 60 capsules | Adamas Pharma, LLC |
| 70482-0085-61 | AMANTADINE 68.5 mg/1 capsule, coated pellets | bottle of 60 capsules | Adamas Pharma, LLC |
Source: the FDA NDC Directory, current listings only. Only packages sold under Gocovri’s own FDA approval (NDA 208944) are listed, never a generic. Some codes belong to companies that repackage Gocovri: it is the same medicine in a different package.
What a Generic Gocovri Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Gocovri
Is there a generic for Gocovri right now?
Yes. The FDA NDC Directory lists a generic amantadine hydrochloride from 46 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Gocovri go generic?
It already has. The FDA NDC Directory lists a generic amantadine hydrochloride from 46 companies, so ask your pharmacy whether it can fill your prescription with one.
Will generic amantadine hydrochloride be the same as Gocovri?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. At least 17 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid over 95% less once six or more companies sold a generic. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Gocovri?
Yes. The FDA Orange Book lists approved generic versions from 17 companies, the first approved in August 1986: Upsher Smith Laboratories LLC, Sandoz Inc, Chartwell Rx Sciences LLC, Aurobindo Pharma USA Inc and 13 more. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
When does the Gocovri patent expire?
The FDA Orange Book lists 13 patents for Gocovri; the last runs to August 2038. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (March 2030) weighs all of that.
Has anyone challenged the Gocovri patents?
Yes. The first patent challenge to Gocovri reached the FDA in January 2018, from one company on that first day. The FDA approved a first challenger’s generic in August 2024, and the list records no sale by a first challenger yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
Changes to This Projection
- First generic expected March 2030 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- EmerphedEphedrine Sulfate2027 to 2028
- VyzultaLatanoprostene Bunod2028 to 2029
- SteglujanErtugliflozin and Sitagliptin PhosphateDecember 2031
- Jornay PMMethylphenidate HydrochlorideMarch 2032
- OpzeluraRuxolitinib Phosphate2034 to 2035
- AtorvaliqAtorvastatin CalciumTBD no date yet
About Gocovri
- Generic name amantadine hydrochloride
- How it is taken By mouth
- Company Supernus Pharmaceuticals Inc
- Patent challenges Since January 2018 (FDA)
- More drugs Brand-name drugs starting with G
- Have a question? A pharmacist answers, free. Ask about Gocovri
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.